Ptc Therapeutics Stock Today
| PTCT Stock | USD 56.98 1.51 2.72% |
PerformanceGood
| Odds Of DistressLow
|
PTC Therapeutics is selling for under 56.98 as of the 19th of March 2025; that is 2.72 percent increase since the beginning of the trading day. The stock's last reported lowest price was 55.0. PTC Therapeutics has less than a 11 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of June 2013 | Category Healthcare | Classification Health Care |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. The company has 78.87 M outstanding shares of which 3.7 M shares are at this time shorted by private and institutional investors with about 4.91 trading days to cover. More on PTC Therapeutics
Moving together with PTC Stock
Moving against PTC Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
PTC Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Stuart Peltz | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPTC Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand PTC Therapeutics' financial leverage. It provides some insight into what part of PTC Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PTC Therapeutics (PTCT) is traded on NASDAQ Exchange in USA. It is located in 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059 and employs 939 people. PTC Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.51 B. PTC Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 78.87 M outstanding shares of which 3.7 M shares are at this time shorted by private and institutional investors with about 4.91 trading days to cover.
PTC Therapeutics currently holds about 288.43 M in cash with (107.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01.
Check PTC Therapeutics Probability Of Bankruptcy
Ownership AllocationPTC Therapeutics secures a total of 78.87 Million outstanding shares. The majority of PTC Therapeutics outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to secure positions in PTC Therapeutics to benefit from reduced commissions. Therefore, outside corporations are subject to a different set of regulations than regular investors in PTC Therapeutics. Please pay attention to any change in the institutional holdings of PTC Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that around one million seven hundred ninety-eight thousand two hundred twenty-two invesors are currently shorting PTC Therapeutics expressing very little confidence in its future performance.
Check PTC Ownership Details
PTC Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2024-12-31 | 1.5 M | |
| Point72 Asset Management, L.p. | 2024-12-31 | 1.4 M | |
| Franklin Resources Inc | 2024-12-31 | 1.3 M | |
| Nuveen Asset Management, Llc | 2024-12-31 | 1.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | |
| Ubs Group Ag | 2024-12-31 | 1.1 M | |
| Blackstone Inc | 2024-12-31 | 1.1 M | |
| Driehaus Capital Management Llc | 2024-12-31 | 1 M | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 826.5 K | |
| Vanguard Group Inc | 2024-12-31 | 9.2 M | |
| Blackrock Inc | 2024-12-31 | 7.9 M |
PTC Therapeutics Historical Income Statement
PTC Stock Against Markets
PTC Therapeutics Corporate Management
| Christine CPA | Chief VP | Profile | |
| Christine Utter | Principal Financial Officer, Principal Accounting Officer, Treasurer | Profile | |
| Murad Husain | Senior Affairs | Profile | |
| Lee MD | Executive Officer | Profile | |
| Ellen Welch | Chief Officer | Profile | |
| FACS FACS | Chief Officer | Profile | |
| Don Mankoff | Executive Counsel | Profile |
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.